Enanta Pharmaceuticals Inc (ENTA)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

500 ARSENAL STREET WATERTOWN, MA 02472

Enanta Pharmaceuticals, Inc., a biotechnology company, engages in the development of small molecule drugs for the infectious disease areas. Its product candidates include ABT-450, an inhibitor of NS3 protease that is in Phase III clinical trials for the treatment of hepatitis C virus (HCV) infection; EDP-239, an NS5A Inhibitor for HCV infection; EDP-546, a Cyclophilin inhibitor, which is in preclinical studies for HCV infection treatment; and Nucleotide Polymerase inhibitor for HCV infection.

Data as of 2020-08-01
Market Cap917.195 Million Shares Outstanding20.004 Million Avg 30-day Volume168.713 Thousand
P/E Ratio42.0 Dividend Yield EPS1.12
Price/Sales6.975 Price cash flow ratio25.7 Price free cash flow ratio27.3
Book Value24.29 Price to Tangible Book1.93 Alpha0.0
Short Interest Ratio % Short Interest to Float R-squared0.023428
BETA0.475733 52-week High/Low76.16 / 38.4 Stddev0.133725
View SEC Filings from ENTA instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 2 2 (0.13%)
13F Filers holding this stock: 153 43 (2.82%)
Aggregate 13F shares on 03/31/2020: 17.688 Million 8.717 Million
Aggregate 13F shares on 12/31/2019: 18.399 Million 8.336 Million
Percent change: -3.87% 4.57%
Funds creating new positions: 20 4
Funds Adding to an existing position: 61 18
Funds closing out their position: 35 19
Funds reducing their position: 48 16
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ENTA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ENTA BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

1.7 Thousand total shares from 1 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

GARDINER NATHANIEL S. SR. VP & GENERAL COUNSEL

  • Officer
45,916 2020-08-05 7

PETERSON KRISTINE

0 2020-07-13 1

GOLUMBESKI GEORGE

  • Director
0 2020-07-06 1

FOLETTA MARK G

  • Director
0 2020-06-29 2

CARTER BRUCE L A

2,000 2020-05-18 1

MELLETT PAUL J TREASURER AND CFO

  • Officer
42,824 2020-05-05 4

VANCE TERRY

  • Director
0 2020-02-26 1

RUSSELL LESLEY

  • Director
0 2020-02-26 1

OR YAT SUN SR. VP & CSO

  • Officer
305,915 2020-02-12 3

LULY JAY R. PRESIDENT AND CEO

  • Officer
  • Director
649,689 2020-02-12 4

ADDA NATHALIE SR. VP & CHIEF MEDICAL OFFICER

  • Officer
15,634 2020-02-12 3

BUCKLEY STEPHEN JR.

  • Director
0 2019-02-28 0

OCAIN TIM SENIOR VICE PRESIDENT

  • Officer
17,547 2019-02-12 0

AFTING ERNST-GUENTER

  • Director
0 2016-02-11 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

GARDINER NATHANIEL S. - Officer SR. VP & GENERAL COUNSEL

2020-08-05 M 1,666 d 15,334 45,916.00 direct

GARDINER NATHANIEL S. - Officer SR. VP & GENERAL COUNSEL

2020-08-05 M 1,666 $30.00 a 29,271 45,916.00 direct

FOLETTA MARK G - Director

2020-06-29 A 17,000 a 17,000 0.00 direct
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments